Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorDeisenhammer, Florian
dc.contributor.authorArrambide, Georgina
dc.contributor.authorBanwell, Brenda Louise
dc.contributor.authorCoetzee, Timothy
dc.contributor.authorGnanapavan, Sharmilee
dc.contributor.authorHegen, Harald
dc.contributor.authorMontalban, Xavier
dc.date.accessioned2025-11-17T07:27:42Z
dc.date.available2025-11-17T07:27:42Z
dc.date.issued2025-10
dc.identifier.citationDeisenhammer F, Hegen H, Arrambide G, Banwell BL, Coetzee T, Gnanapavan S, et al. Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis. eBioMedicine. 2025 Oct;120:105905.
dc.identifier.issn2352-3964
dc.identifier.urihttp://hdl.handle.net/11351/14075
dc.descriptionCerebrospinal fluid; Criteria; Diagnosis
dc.description.abstractThe 2024 McDonald diagnostic criteria for Multiple Sclerosis (MS) introduce kappa free light chains (κ-FLC) detection in cerebrospinal fluid (CSF) which can be used interchangeably with oligoclonal IgG bands (OCB) to demonstrate intrathecal immunoglobulin synthesis. Diagnostic sensitivity and specificity of κ-FLC is equal to OCB on a 95% confidence level. In rare cases determination of both, κ-FLC and OCB should be considered as the concordance rate is around 90%. We recommend calculating the κ-FLC index with values of ≥6.1 performing best for diagnosing MS. Validated turbidimetric or nephelometric assays should be applied for which proficiency testing programs are available. There is some prognostic use of the κ-FLC index with higher values predicting higher disease activity. Neurofilament light (NfL) should not be used for diagnostic purposes although it might be useful for prognosis and disease monitoring. All recommendations apply to paediatric and adult relapsing as well as progressive onset MS.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofserieseBioMedicine;120
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectEsclerosi múltiple - Diagnòstic
dc.subjectLíquid cefaloraquidi
dc.subject.meshMultiple Sclerosis
dc.subject.mesh/diagnosis
dc.subject.meshCerebrospinal Fluid
dc.titlePositive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.ebiom.2025.105905
dc.subject.decsesclerosis múltiple
dc.subject.decs/diagnóstico
dc.subject.decslíquido cefalorraquídeo
dc.relation.publishversionhttps://doi.org/10.1016/j.ebiom.2025.105905
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Deisenhammer F, Hegen H] Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. [Arrambide G] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Banwell BL] Department of Pediatrics, Johns Hopkins University, Baltimore, USA. [Coetzee T] National Multiple Sclerosis Society, New York, NY, USA. [Gnanapavan S] Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. [Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Universitat de Vic/Central de Catalunya (UVic-UCC), Spain
dc.identifier.pmid40967951
dc.identifier.wos001594580100002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record